GS-9822

CAS No. 2219362-41-9

GS-9822( GS9822 | GS 9822 )

Catalog No. M13539 CAS No. 2219362-41-9

GS-9822 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 3 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1773 Get Quote
50MG 3582 Get Quote
100MG 4950 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GS-9822
  • Note
    Research use only, not for human use.
  • Brief Description
    GS-9822 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 3 nM.
  • Description
    GS-9822 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 3 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GS9822 | GS 9822
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2219362-41-9
  • Formula Weight
    659.242
  • Molecular Formula
    C36H39ClN4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1=CC2=C(C(=C1C(C(=O)O)OC(C)(C)C)C3=CC=C(C=C3)Cl)SC(=N2)C4=CC5=C(C=C4)N(N=C5C6CCN(CC6)C7COC7)C
  • Chemical Name
    (S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • NBD-14189

    NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63?nM against some clinical isolates.

  • PF-46396

    PF-46396 is a?specific small-molecule inhibitor of HIV-1 Gag maturation that interferes specifically with the cleavage of the CA/SP1 (p25) Gag precursor to the mature CA (p24) protein.

  • BNM-III-170 trifluor...

    BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.